Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
0.875
-0.085 (-8.81%)
At close: Feb 21, 2025, 4:00 PM
0.884
+0.009 (1.01%)
After-hours: Feb 21, 2025, 7:01 PM EST
Outset Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Outset Medical stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 356.93% from the current stock price of 0.88.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 7, 2025.
Analyst Ratings
The average analyst rating for Outset Medical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $3 | Hold | Reiterates | $3 | +242.70% | Jan 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $6 → $3 | Buy → Hold | Downgrades | $6 → $3 | +242.70% | Aug 8, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $9 → $3 | Strong Buy | Maintains | $9 → $3 | +242.70% | Aug 8, 2024 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $5 → $6 | Hold → Buy | Upgrades | $5 → $6 | +585.40% | Jun 21, 2024 |
| BTIG | BTIG | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +585.40% | Apr 8, 2024 |
Financial Forecast
Revenue This Year
116.06M
from 130.38M
Decreased by -10.98%
Revenue Next Year
124.96M
from 116.06M
Increased by 7.67%
EPS This Year
-1.91
from -3.48
EPS Next Year
-0.89
from -1.91
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 118.9M | 128.5M | 150.5M | |||
| Avg | 116.1M | 125.0M | 143.1M | |||
| Low | 109.7M | 117.6M | 130.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -8.8% | 10.7% | 20.4% | |||
| Avg | -11.0% | 7.7% | 14.5% | |||
| Low | -15.9% | 1.3% | 4.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.92 | -0.25 | -0.18 | |||
| Avg | -1.91 | -0.89 | -0.64 | |||
| Low | -1.84 | -1.36 | -1.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.